Related Experiment Video
Updated: Jan 26, 2026
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with
D Giugliano1, P Chiodini2, M I Maiorino3
1Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, Università della Campania Luigi Vanvitelli, Piazza L. Miraglia, 80131, Naples, Italy. dario.giugliano@unicampania.it.
Insights
Lowering hemoglobin A1c (HbA1c) by 0.5% significantly reduces major adverse cardiovascular events (MACE) risk by 20%. This highlights the crucial role of blood glucose reduction in cardiovascular outcomes with modern diabetes medications.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Cardiovascular outcome trials (CVOTs) evaluate newer glucose-lowering drugs.
- The relationship between hemoglobin A1c (HbA1c) reduction and cardiovascular risk is not fully understood.
Purpose of the Study:
- To meta-analyze the association between HbA1c reduction and cardiovascular outcomes in CVOTs.
- To quantify the impact of HbA1c reduction on major adverse cardiovascular events (MACE).
Main Methods:
- A random-effects meta-analysis of 12 CVOTs was performed.
- HbA1c reduction was stratified into three groups: <0.3%, 0.3-0.5%, and ≥0.5% (drug vs. placebo).
- Meta-regression evaluated the relationship between HbA1c reduction and MACE risk.
Main Results:
- A significant relationship was found between HbA1c reduction and MACE risk reduction (P=0.002).
- A 0.5% reduction in HbA1c was associated with a 20% hazard ratio reduction for MACE (95% CI 4-33%).
- This finding explained 94.1% of the between-study variance.
Conclusions:
- Blood glucose reduction plays a significant role in mitigating MACE risk with newer glucose-lowering drugs.
- This includes drugs like DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors.
- The degree of HbA1c reduction is a critical factor in achieving cardiovascular benefits.
Purpose:
We did a meta-analysis with meta-regression to evaluate the relationship between hemoglobin A1c (A1C) reduction and the primary CV outcome of cardiovascular outcome trials (CVOTs).
Methods:
We used a random effects meta-analysis of the 12 CVOTs to quantify the effect of A1C reduction on major cardiovascular events (MACE) risk by stratifying the difference in achieved A1C (drug vs placebo) in three strata: A1c < 0.3%, A1c ≥ 0.3% and < 0.5%, and A1c ≥ 0.5%.
Results:
We found a relation between the reduction in achieved A1C and the hazard ratio reduction for MACE (P = 0.002), explaining almost all (94.1%) the between-study variances: lowering A1C by 0.5% conferred a significant HRR of 20% (95% CI 4-33%) for MACE.
Conclusions:
Blood glucose reduction may play a more important role than previously thought in reducing the risk of MACE during treatment with the newer glucose-lowering drugs, including peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors.
More Related Videos
Related Concept Videos
01:14Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
01:29Assessment of the Cardiovascular System II: Inspection
Head and Neck
01:25Assessment of the Cardiovascular System IV: Auscultation
Normal Heart Sounds
S1 (First Heart Sound)-
S1 is made by the closure of the mitral and tricuspid valves (atrioventricular valves), marking the beginning of systole.
S2 (Second Heart Sound)-
S2 is made by the closure of the aortic and pulmonic valves (semilunar valves), marking the end of the systole.